<DOC>
	<DOCNO>NCT00063258</DOCNO>
	<brief_summary>The goal clinical research study learn safety effectiveness OSI-774 combined standard chemotherapy ( carboplatin paclitaxel ) surgery treatment non-small cell lung cancer .</brief_summary>
	<brief_title>Tarceva Surgery Resectable Stage IIIA ( N2 ) IIIB ( T4 N2 ) Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>This phase II , single institution open label randomize trial induction carboplatin paclitaxel plus/minus daily oral OSI-774 patient potentially resectable NSCLC stage IIIA IIIB ( T4 satellite nodule invasion T4 structure malignant effusion . ) N3 disease exclude . Patients require pathologically demonstrate N2 disease via mediastinoscopy . Forty patient treat 3 course chemotherapy follow surgery . Ten patient randomized chemotherapy alone 30 patient chemotherapy plus OSI-774 . The 10 patient serve chemotherapy alone control molecular endpoint analysis . OSI-774 stop night surgery . At time surgery , pathologic response determine . Following surgery , patient treat consolidation radiation therapy positive margin N2 lymph node time resection . Patients N2 disease surgery option consolidation radiation therapy require do . Patients able tolerate radiation even N2 disease positive margin surgery may continue study . This follow maintenance OSI-774 patient arm study . OSI-774 continue maintenance maximum 2 year follow surgery . Tissue molecular study obtain pretreatment either time diagnostic biopsy mediastinoscopy . Post-treatment tissue obtain time surgery . This tissue assay define molecular endpoint use immunohistochemistry , immunoprecipitation mRNA expression analysis . Blood , urine , hair follicle , skin sample also collect patient consent provide .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Must sign consent LAB030383 2 . Pathologic documentation NSCLC 3 . Stage IIIA IIIB ( T4 satellite nodule invasion T4 structure malignant effusion ) patient require mediastinoscopy positive N2 , potentially resectable disease . N3 disease exclude . 4 . Measurable disease 5 . Zubrod performance status 0 1 6 . Calculated postresectional FEV1 &gt; 40 % 7 . WBC &gt; 4000/l , ANC &gt; 1500/l , platelet &gt; 100,000/l 8 . Serum creatinine &lt; 1.5 ULN calculate creatinine &gt; 50 cc/min 9 . Total serum bilirubin &lt; 1.5 x ULN SGPT SGOT &lt; 2 X ULN 10 . The following must complete within 28 day registration : CT scan chest upper abdomen include adrenal . Mediastinoscopy document ipsilateral nodal involvement exclude N3 disease Blood test , pulmonary function test The following must complete within 2 month registration : Pet scan If CT PET do 28 day , CT need repeat bone scan rule bone metastases 1 . No prior chemotherapy radiation NSCLC 2 . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree least five year . If patient suspect known basal squamous skin cancer , maybe treat induction chemotherapy complete time thoracotomy . 3 . No postobstructive pneumonia serious infection serious underlie medical condition would impair ability patient receive protocol treatment , include prior allergic reaction drug contain cremophor . 4 . Pregnant nursing woman may participate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>NSCLC</keyword>
</DOC>